Literature DB >> 9043671

Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210.

H Osada1, C B Cui, R Onose, F Hanaoka.   

Abstract

We have established a bioassay system using a mouse cdc2 mutant cell line, tsFT210, to detect inhibitors of the mammalian cell cycle. When cultured at the high temperature, restrictive temperature at 39.4 degrees C, tsFT210 cells can be arrested at G2 phase and are large in size. Four hours after release from G2 arrest, the cells entered into the G1 phase. At this time, G1 phase cells were easily discriminated from the G2/M-cells by their size under microscopic observation. The cell-morphology-based bioassay utilizing tsFT210 cells is very simple and sensitive for detecting cdc2 kinase inhibitors and also G2/M-phase inhibitors of the mammalian cell cycle. To demonstrate the merits of this bioassay, the effects of protein kinase inhibitors isolated from actinomycetes were investigated. RK-286C and RK-1409, which are structurally related to staurosporine, inhibited cell cycle progression at the G2 phase in both G2-synchronized and nonsynchronized cultures of tsFT210 cells. Another kinase inhibitor, sangivamycin, inhibited cell cycle progression at the G2 phase of cells released from temperature arrest but did not inhibit that of the exponentially growing cells. Using the bioassay system, we carried out screening of the cell cycle inhibitors from the microbial metabolites and have discovered several new inhibitors, including novel compounds such as tryprostatins A, B and acetophthalidin. Thus, this bioassay allowed for the detection of cell cycle inhibitors and provided a convenient and useful method for the screening of new inhibitors from the microbial metabolites.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9043671     DOI: 10.1016/s0968-0896(96)00207-6

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Terminating Catalytic Asymmetric Heck Cyclizations by Stereoselective Intramolecular Capture of η-Allylpalladium Intermediates: Total Synthesis of (-)-Spirotryprostatin B and Three Stereoisomers.

Authors:  Larry E Overman; Mark D Rosen
Journal:  Tetrahedron       Date:  2010-08-14       Impact factor: 2.457

2.  Structure-function analyses of cytochrome P450revI involved in reveromycin A biosynthesis and evaluation of the biological activity of its substrate, reveromycin T.

Authors:  Shunji Takahashi; Shingo Nagano; Toshihiko Nogawa; Naoki Kanoh; Masakazu Uramoto; Makoto Kawatani; Takeshi Shimizu; Takeshi Miyazawa; Yoshitsugu Shiro; Hiroyuki Osada
Journal:  J Biol Chem       Date:  2014-09-25       Impact factor: 5.157

3.  An overproduction of astellolides induced by genetic disruption of chromatin-remodeling factors in Aspergillus oryzae.

Authors:  Yasutomo Shinohara; Makoto Kawatani; Yushi Futamura; Hiroyuki Osada; Yasuji Koyama
Journal:  J Antibiot (Tokyo)       Date:  2015-07-01       Impact factor: 2.649

Review 4.  Mechanism targeted discovery of antitumor marine natural products.

Authors:  Dale G Nagle; Yu-Dong Zhou; Flor D Mora; Kaleem A Mohammed; Yong-Pil Kim
Journal:  Curr Med Chem       Date:  2004-07       Impact factor: 4.530

5.  Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein.

Authors:  Hiteshkumar D Jain; Chunchun Zhang; Shuo Zhou; Hao Zhou; Jun Ma; Xiaoxiang Liu; Xuebin Liao; Amy M Deveau; Christine M Dieckhaus; Michael A Johnson; Kirsten S Smith; Timothy L Macdonald; Hideaki Kakeya; Hiroyuki Osada; James M Cook
Journal:  Bioorg Med Chem       Date:  2008-02-20       Impact factor: 3.641

6.  Tryprostatin A, a specific and novel inhibitor of microtubule assembly.

Authors:  T Usui; M Kondoh; C B Cui; T Mayumi; H Osada
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

Review 7.  Screening and identification of inhibitors of endoplasmic reticulum stress-induced activation of the IRE1α-XBP1 branch.

Authors:  Etsu Tashiro
Journal:  J Antibiot (Tokyo)       Date:  2019-08-09       Impact factor: 2.649

8.  Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing.

Authors:  M Ri; E Tashiro; D Oikawa; S Shinjo; M Tokuda; Y Yokouchi; T Narita; A Masaki; A Ito; J Ding; S Kusumoto; T Ishida; H Komatsu; Y Shiotsu; R Ueda; T Iwawaki; M Imoto; S Iida
Journal:  Blood Cancer J       Date:  2012-07-20       Impact factor: 11.037

9.  The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.

Authors:  Y Akashi; I Okamoto; M Suzuki; K Tamura; T Iwasa; S Hisada; T Satoh; K Nakagawa; K Ono; M Fukuoka
Journal:  Br J Cancer       Date:  2007-05-01       Impact factor: 7.640

10.  Transcription- and phosphorylation-dependent control of a functional interplay between XBP1s and PINK1 governs mitophagy and potentially impacts Parkinson disease pathophysiology.

Authors:  Wejdane El Manaa; Eric Duplan; Thomas Goiran; Inger Lauritzen; Loan Vaillant Beuchot; Sandra Lacas-Gervais; Vanessa Alexandra Morais; Han You; Ling Qi; Mario Salazar; Umut Ozcan; Mounia Chami; Frédéric Checler; Cristine Alves da Costa
Journal:  Autophagy       Date:  2021-05-24       Impact factor: 16.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.